Universal GPCR Activity Sensor for Next Generation Drug Discovery
This project by a consortium of academic labs and small biotech companies concerns a new key innovation for the development of drugs targeting G protein-coupled receptors (GPCRs). GPCRs are the most important class of therapeutic...
This project by a consortium of academic labs and small biotech companies concerns a new key innovation for the development of drugs targeting G protein-coupled receptors (GPCRs). GPCRs are the most important class of therapeutic targets, both for current drugs and those under development, covering about a third of the €1.2 trillion pharmaceutical market. Recent research has revealed that GPCRs do not function as simple on/off switches but instead can adopt multiple conformations leading to complex textures of downstream effects. Functionally selective drugs modulate the GPCR structure to stimulate certain downstream pathways over others. In the search for this next generation of better drugs, the pharmaceutical industry currently employs multiple (10+) distinct GPCR assays, performed in non-identical cellular contexts, and misleading readouts from this approach contribute significantly to costly drug failure. Here we propose a radically new single-assay technology platform that will enable detection and functional classification of drug candidates with superior confidence compared to today's approaches. Its unique design supports streamlined drug discovery from the test tube to the native disease-relevant cell, as well as the capacity to efficiently harness artificial intelligence (AI) in the design of better drugs. The technology is based upon highly informative fluorescent sensor reagents that react to different receptor conformations with subtle, flexible changes in their structure. In this Pathfinder project, our main objective is to demonstrate that the conformational fingerprints generated by these sensors correlate to specific cellular signalling profiles, i.e. GPCR activity states (proof of principle). We believe that the UniSens platform will become the standard tool for early drug development and could be a game-changer in the search for safer, more effective drugs.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.